Old asthma drug shows promise for rare genetic disorder

NCT ID NCT03029429

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether theophylline, a drug used for asthma, can help people with pseudohypoparathyroidism lose weight and improve blood sugar control. The study includes 29 obese participants aged 13 and older. Researchers will measure changes in body mass index and glucose tolerance over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

theophylline

What this could lead to

If successful, this could point toward a new treatment to help manage weight and blood sugar in people with pseudohypoparathyroidism.

What could go wrong

This is a small early-phase trial with only 29 participants, so results may not apply to everyone. Theophylline can cause side effects like nausea or heart issues.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSEUDOHYPOPARATHYROIDISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pseudohypoparathyroidism pseudohypoparathyroidism type 1A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Jaclyn Tamaroff

    Nashville, Tennessee, 37212, United States